Effects of concurrent HER2-directed therapy on development of cerebral radionecrosis after stereotactic radiotherapy: a systematic review.

Journal: Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]
Published Date:

Abstract

PURPOSE: With increasing use of human epithelial growth factor receptor two (HER2)-targeted therapies, outcomes for numerous breast cancer patients have improved. Nevertheless, patients with HER2-positive tumours face a comparatively heightened risk for developing brain metastases (BM), which are often treated with stereotactic radiosurgery (SRS). Radionecrosis represents one of the clinically most significant adverse events of SRS. However, a knowledge gap remains regarding the effects of concurrent use of HER2-targeted therapies with SRS on development of radionecrosis, given conflicting findings in existing studies.

Authors

  • Clara Grinzinger
    Klinik für Strahlentherapie und Radioonkologie, Universitätsklinikum Augsburg, Stenglinstraße 2, 86156, Augsburg, Germany. clara.grinzinger@uni-a.de.
  • Georg Stüben
    Klinik für Strahlentherapie und Radioonkologie, Universitätsklinikum Augsburg, Stenglinstraße 2, 86156, Augsburg, Germany.
  • Maria Neu
    Klinik für Strahlentherapie und Radioonkologie, Universitätsklinikum Augsburg, Stenglinstraße 2, 86156, Augsburg, Germany.
  • Anna Rubeck
    University of Augsburg, Institute of Mathematics, Universitätsstraße 2, 86159, Augsburg, Germany.
  • Stefan Schiele
    University of Augsburg, Institute of Mathematics, Universitätsstraße 2, 86159, Augsburg, Germany.
  • Lars Behrens
    Klinik für Diagnostische und Interventionelle Neuroradiologie, Universitätsklinikum Augsburg, Stenglinstraße 2, 86156, Augsburg, Germany.
  • Klaus-Henning Kahl
    Klinik für Strahlentherapie und Radioonkologie, Universitätsklinikum Augsburg, Stenglinstraße 2, 86156, Augsburg, Germany. klaushenning.kahl@uk-augsburg.de.

Keywords

No keywords available for this article.